169 related articles for article (PubMed ID: 17652621)
21. Phosphorylated CIS suppresses the Epo or JAK2 V617F mutant-triggered cell proliferation through binding to EpoR.
Funakoshi-Tago M; Moriwaki T; Ueda F; Tamura H; Kasahara T; Tago K
Cell Signal; 2017 Feb; 31():41-57. PubMed ID: 28038963
[TBL] [Abstract][Full Text] [Related]
22. The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3.
Hookham MB; Elliott J; Suessmuth Y; Staerk J; Ward AC; Vainchenker W; Percy MJ; McMullin MF; Constantinescu SN; Johnston JA
Blood; 2007 Jun; 109(11):4924-9. PubMed ID: 17317861
[TBL] [Abstract][Full Text] [Related]
23. [Effect of SOCS1 Gene on Growth Inhibition of Acute Myeloid Leukemia Cells Mediated by JAK2/STAT Signaling Pathway].
Zhang XH; Luo JM; Yang L; Liu XJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Oct; 28(5):1496-1503. PubMed ID: 33067944
[TBL] [Abstract][Full Text] [Related]
24. Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line.
Melzner I; Bucur AJ; Brüderlein S; Dorsch K; Hasel C; Barth TF; Leithäuser F; Möller P
Blood; 2005 Mar; 105(6):2535-42. PubMed ID: 15572583
[TBL] [Abstract][Full Text] [Related]
25. Suppressor of cytokine signaling 1 protects rat pancreatic islets from cytokine-induced apoptosis through Janus kinase/signal transducers and activators of transcription pathway.
Sun Q; Xiang RL; Yang YL; Feng K; Zhang K; Ding WY
Chin Med J (Engl); 2013 Nov; 126(21):4048-53. PubMed ID: 24229672
[TBL] [Abstract][Full Text] [Related]
26. Nectin-4 co-stimulates the prolactin receptor by interacting with SOCS1 and inhibiting its activity on the JAK2-STAT5a signaling pathway.
Maruoka M; Kedashiro S; Ueda Y; Mizutani K; Takai Y
J Biol Chem; 2017 Apr; 292(17):6895-6909. PubMed ID: 28258213
[TBL] [Abstract][Full Text] [Related]
27. Deregulated JAK/STAT signalling in lymphomagenesis, and its implications for the development of new targeted therapies.
Scott LM; Gandhi MK
Blood Rev; 2015 Nov; 29(6):405-15. PubMed ID: 26123794
[TBL] [Abstract][Full Text] [Related]
28. SOCS1 regulates CCR7 expression and migration of CD4+ T cells into peripheral tissues.
Yu CR; Mahdi RM; Liu X; Zhang A; Naka T; Kishimoto T; Egwuagu CE
J Immunol; 2008 Jul; 181(2):1190-8. PubMed ID: 18606672
[TBL] [Abstract][Full Text] [Related]
29. Trichostatin A, a histone deacetylase inhibitor, suppresses JAK2/STAT3 signaling via inducing the promoter-associated histone acetylation of SOCS1 and SOCS3 in human colorectal cancer cells.
Xiong H; Du W; Zhang YJ; Hong J; Su WY; Tang JT; Wang YC; Lu R; Fang JY
Mol Carcinog; 2012 Feb; 51(2):174-84. PubMed ID: 21520296
[TBL] [Abstract][Full Text] [Related]
30. STAT6 is a cargo of exportin 1: Biological relevance in primary mediastinal B-cell lymphoma.
Miloudi H; Leroy K; Jardin F; Sola B
Cell Signal; 2018 Jun; 46():76-82. PubMed ID: 29501729
[TBL] [Abstract][Full Text] [Related]
31. REX1 promotes EMT-induced cell metastasis by activating the JAK2/STAT3-signaling pathway by targeting SOCS1 in cervical cancer.
Zeng YT; Liu XF; Yang WT; Zheng PS
Oncogene; 2019 Oct; 38(43):6940-6957. PubMed ID: 31409905
[TBL] [Abstract][Full Text] [Related]
32. Dormant tumor cells develop cross-resistance to apoptosis induced by CTLs or imatinib mesylate via methylation of suppressor of cytokine signaling 1.
Saudemont A; Hamrouni A; Marchetti P; Liu J; Jouy N; Hetuin D; Colucci F; Quesnel B
Cancer Res; 2007 May; 67(9):4491-8. PubMed ID: 17483365
[TBL] [Abstract][Full Text] [Related]
33. STAT6 and STAT1 are essential antagonistic regulators of cell survival in classical Hodgkin lymphoma cell line.
Baus D; Nonnenmacher F; Jankowski S; Döring C; Bräutigam C; Frank M; Hansmann ML; Pfitzner E
Leukemia; 2009 Oct; 23(10):1885-93. PubMed ID: 19440213
[TBL] [Abstract][Full Text] [Related]
34. Autocrine LTA signaling drives NF-κB and JAK-STAT activity and myeloid gene expression in Hodgkin lymphoma.
von Hoff L; Kärgel E; Franke V; McShane E; Schulz-Beiss KW; Patone G; Schleussner N; Kolesnichenko M; Hübner N; Daumke O; Selbach M; Akalin A; Mathas S; Scheidereit C
Blood; 2019 Mar; 133(13):1489-1494. PubMed ID: 30696620
[TBL] [Abstract][Full Text] [Related]
35. Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma.
Guiter C; Dusanter-Fourt I; Copie-Bergman C; Boulland ML; Le Gouvello S; Gaulard P; Leroy K; Castellano F
Blood; 2004 Jul; 104(2):543-9. PubMed ID: 15044251
[TBL] [Abstract][Full Text] [Related]
36. Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases.
Teofili L; Martini M; Cenci T; Guidi F; Torti L; Giona F; Foà R; Leone G; Larocca LM
Int J Cancer; 2008 Oct; 123(7):1586-92. PubMed ID: 18623127
[TBL] [Abstract][Full Text] [Related]
37. JAK2 inhibitors in the treatment of myeloproliferative neoplasms.
Tibes R; Bogenberger JM; Geyer HL; Mesa RA
Expert Opin Investig Drugs; 2012 Dec; 21(12):1755-74. PubMed ID: 22991927
[TBL] [Abstract][Full Text] [Related]
38. JAK/STAT signal transduction: regulators and implication in hematological malignancies.
Valentino L; Pierre J
Biochem Pharmacol; 2006 Mar; 71(6):713-21. PubMed ID: 16426581
[TBL] [Abstract][Full Text] [Related]
39. Type III Interferon Induces Distinct SOCS1 Expression Pattern that Contributes to Delayed but Prolonged Activation of Jak/STAT Signaling Pathway: Implications for Treatment Non-Response in HCV Patients.
Liu B; Chen S; Guan Y; Chen L
PLoS One; 2015; 10(7):e0133800. PubMed ID: 26193702
[TBL] [Abstract][Full Text] [Related]
40. Pure curcumin increases the expression of SOCS1 and SOCS3 in myeloproliferative neoplasms through suppressing class I histone deacetylases.
Chen CQ; Yu K; Yan QX; Xing CY; Chen Y; Yan Z; Shi YF; Zhao KW; Gao SM
Carcinogenesis; 2013 Jul; 34(7):1442-9. PubMed ID: 23430957
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
